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A B S T R A C T
With the aim to develop alternative therapeutic tools for the treatment of resistant cancers, here we
propose targeted Pluronic1 P123/F127 mixed micelles (PMM) delivering niclosamide (NCL) as a
repositioning strategy to treat multidrug resistant non-small lung cancer cell lines. To build
multifunctional PMM for targeting and imaging, Pluronic1 F127 was conjugated with biotin, while
Pluronic1 P123 was ﬂuorescently tagged with rhodamine B, in both cases at one of the two hydroxyl end
groups. This design intended to avoid any interference of rhodamine B on biotin exposition on PMM
surface, which is a key fundamental for cell trafﬁcking studies. Biotin-decorated PMM were internalized
more efﬁciently than non-targeted PMM in A549 lung cancer cells, while very low internalization was
found in NHI3T3 normal ﬁbroblasts. Biotin-decorated PMM entrapped NCL with good efﬁciency,
displayed sustained drug release in protein-rich media and improved cytotoxicity in A549 cells as
compared to free NCL (P < 0.01). To go in depth into the actual therapeutic potential of NCL-loaded PMM,
a cisplatin-resistant A549 lung cancer cell line (CPr-A549) was developed and its multidrug resistance
tested against common chemotherapeutics. Free NCL was able to overcome chemoresistance showing
cytotoxic effects in this cell line ascribable to nucleolar stress, which was associated to a signiﬁcant
increase of the ribosomal protein rpL3 and consequent up-regulation of p21. It is noteworthy that biotin-
decorated PMM carrying NCL at low doses demonstrated a signiﬁcantly higher cytotoxicity than free NCL
in CPr-A549. These results point at NCL-based regimen with targeted PMM as a possible second-line
chemotherapy for lung cancer showing cisplatin or multidrug resistance.
ã 2016 Elsevier B.V. All rights reserved.
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Cancer is the leading cause of mortality worldwide and its
incidence continues to rise (Siegel et al., 2015). Although the
discovery of novel and effective anticancer drugs is a major
research area, it is well known that the development of new
chemotherapeutics in oncology is a lengthy and extremely costly
process. Furthermore, it often results in only slight reduction of* Corresponding authors at: Department of Pharmacy, University of Napoli
Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy.
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0378-5173/ã 2016 Elsevier B.V. All rights reserved.chemotherapy-related side effects and minimal increase in the
overall survival rate. Therefore, alternative approaches to antican-
cer drug discovery are needed.
To reduce pharmaceutical research costs and development
timelines, considerable attention has been devoted to the so called
drug “repositioning” or “repurposing” approach, which entails
ﬁnding novel therapeutic indications for already approved drugs
(Ashburn and Thor, 2004). Some successful repositioning stories,
such as those of minoxidil, sildenaﬁl and raloxifene, are very well
known. Nevertheless, despite several initiatives, only a few drugs
have been successfully approved for new indications (Novac,
2013). In recent years, this approach has been very promising to
identify approved non-cancer drugs that possess anticancer
128 A. Russo et al. / International Journal of Pharmaceutics 511 (2016) 127–139activity, thus abbreviating the development process (Shim and Liu,
2014).
Some studies have reported the inhibitory effects of niclosa-
mide (5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenza-
mide) (NCL), an anthelmintic drug approved for use in humans
for nearly 50 years, on multiple intracellular signalling pathways
(Balgi et al., 2009; Liu et al., 2015; Ren et al., 2010; Sack et al., 2011;
Xiang et al., 2015). The signaling molecules in these pathways are
either over-expressed, constitutively activated or mutated in many
cancer cells, thus making NCL a very intriguing tool for cancer
treatment (Li et al., 2014). Indeed, NCL inhibits the ATP-binding
cassette efﬂux pump ABCG2 (breast cancer resistance protein or
BCRP) (Strouse et al., 2013), which is a protein able to confer Multi
Drug Resistance (MDR) to a broad spectrum of anticancer drugs
(Staud and Pavek, 2005). Furthermore, NCL exhibits antitumor
activity in vitro and in vivo by suppressing the expression of
lipoprotein receptor-related protein (LRP), thus inhibiting Wnt/
b-catenin signaling in human prostate and breast tumor cells. LRP
has been involved in the resistance of ovarian cancer cells to
cisplatin and shown to play an important role in the transport of
cisplatin (Wang et al., 2004).
The major concern related to the therapeutic use of NCL is its
very low solubility and consequent poor dissolution properties in
biological ﬂuids. Furthermore, the bioaccessibility of systemic
anticancer drugs to tumour tissue remains limited and large drug
doses are commonly required to exert a therapeutic effect, with
consequent high toxicity to normal cells and increased incidence of
MDR.
Overwhelming attention is nowadays devoted to novel
polymeric carriers with tailored properties to attain efﬁcient
transport of chemotherapeutics in the body (d’Angelo et al., 2014).
Pluronic1polymers are amphiphilic triblock copolymers of poly
(ethylene oxide) (PEO) and poly(propylene oxide) (PPO), which
self-assemble in aqueous media forming core-shell micelles
(Kabanov et al., 2002). Due to their ability to accommodate
hydrophobic drugs in the PPO core, Pluronic1 micelles have been
proposed to solve solubility issues of several drugs (Alvarez-
Lorenzo et al., 2011). Furthermore, Pluronic1 micelles possess
unique beneﬁcial features for cancer therapy, that is: (i) small size
(<100 nm) useful to prolong drug circulation time and to promote
its passive targeting to solid tumors (Batrakova and Kabanov, 2008;
Zhu et al., 2016); (ii) inhibition of drug efﬂux transporters
overcoming MDR (Alakhova and Kabanov, 2014; Alvarez-Lorenzo
et al., 2011); iii) presence of hydroxyl end groups allowing the
covalent binding of targeting ligands and imaging agents providing
multifunctionality (Ding et al., 2011; Jung et al., 2013; Zhang et al.,
2011).
Recently our group has developed Pluronic1 P123/F127 mixed
micelles that are stable in biologically-relevant media and able to
load and stabilize hydrophobic benzoporphyrin derivatives for
photodynamic therapy application (Pellosi et al., 2016). In analogy
to all PEO-coated nanocarriers, Pluronic1 micelles suffer poor
uptake in cancer cells due to increased surface hydrophilicity,
which can be a drawback when trying to accumulate drug cargo
intracellularly. To overcome this issue, and hopefully improve
therapeutic effects in a biological environment, surface decoration
with small targeting ligands is a common strategy to encourage
carrier accumulation in targeted cells (Stylianopoulos and Jain,
2015). The vitamin biotin, an essential micronutrient that could
give tumor-targeting properties, has been recently proposed to this
purpose. In fact, several cancer cell lines overexpress biotin-
speciﬁc receptors such as avidin, neutravidin, and streptavidin that
facilitate receptor-mediated endocytosis of biotinylated nano-
particles in cancer cells (Chen et al., 2010; Morral-Ruiz et al., 2015).
To track micelles in a biological milieu, a ﬂuorescent probe can be
covalently linked to polymer unimers providing ﬂuorescentmicelles. In fact, imaging-based techniques allow understanding
of micelle dynamic, monitoring their body distribution and real-
time cell uptake, thus bringing tremendous advantages in relating
trafﬁcking to biological effects (Wang et al., 2014).
With this idea in mind, here we have developed a multifunc-
tional platform for the delivery of NCL to cancer cells comprising
Pluronic1 P123/F127 mixed micelles (PMM) surface-decorated
with the vitamin biotin as targeting agent and further engineered
with a ﬂuorescent tag for cell imaging purposes. After formulation
studies aimed at assessing the best conditions to entrap and
release NCL, NCL-loaded biotin-decorated PMM have been
obtained. The role played by biotin decoration on PMM selectivity
toward lung cancer cells, and its consequent cytotoxicity in cells
either sensitive or resistant to cisplatin, were elucidated. We
generated and characterized a cisplatin-resistant non-small lung
cancer cell line, providing a valuable tool for investigating both the
therapeutic potential of NCL to overcome MDR in cancer cells and
the mechanism through which the drug exerts its cytotoxic effect.
2. Materials and methods
2.1. Materials
Pluronic1 P123 (EO20-PO65-EO20, MW = 5750 g mol1) and F127
(EO100-PO65-EO100, MW = 12600 g mol1), biotin, HABA/avidin
reagent, N,N’-dicyclohexylcarbodiimide (DCC), 4-dimethylamino-
pyridine (DMAP), niclosamide (NCL), rhodamine B and trehalose
were obtained from Sigma-Aldrich (Italy). Ethanol, dichloro-
methane, diethyl ether, acetone and acetonitrile were purchased
from Carlo Erba Reagents (Italy). Dimethyl sulfoxide-d6 (DMSO-
d6), D2O and all deuterated solvents for nuclear magnetic
resonance (NMR) spectroscopy were purchased from Merck (Italy).
All the other chemicals were of analytical reagent grade and used
without previous puriﬁcation.
2.2. Synthesis of biotin-conjugated and rhodamine-conjugated
Pluronic1
The synthetic procedure was adapted from the literature (Li
et al., 2010) and was similar for both P123 and F127. For biotin-
conjugated Pluronic1, F127 (5.0 g, 0.40 mmol) was dissolved in
75 mL of dichloromethane followed by the addition of biotin
(0.12 g, 0.48 mmol). For Rhodamine-conjugated Pluronic1, P123
(3.0 g, 0.40 mmol) was dissolved in 75 mL of dichloromethane
followed by the addition of rhodamine B (0.44 g, 0.48 mmol). After
that, DMAP (0.004 g, 0.03 mmol) was added to each reaction ﬂask
and the solution cooled to 0 C. DCC (0.08 g, 0.40 mmol) was added
dropwise via a dropping funnel over 30 min, and the reactions
were carried out for 48 h at room temperature under stirring. The
reaction mixtures were then extracted with a NaHCO3 water
solution (10% v/v). After this step, the organic phases were frozen
overnight and the insoluble substances were removed by ﬁltration.
The organic solutions were then precipitated twice in cold diethyl
ether. The functionalized polymers were ﬁltered and dried
overnight under vacuum.
Biotin-F127 reaction yield = 82%. 1H NMR (300 MHz, DMSO-d6,
TMS), d (ppm): 1.000-1.485 (s, –CH3 b), 1.493 (m, H5, 2H), 2.200 (m,
H3, 2H), 2.821 (m,H5, 2H), 3.105 (m, H4, 2H), 3.260–3.619 (m, –O-
CH2-CH2- a), 4.138 (m, H60, 1H), 4.300 (m, H6, 1H), 6.363 (s, HN2, 1H)
e 6.437 (s, HN1, 1H).
Rhodamine-P123 reaction yield = 68%. 1H NMR (300 MHz,
DMSO-d6, TMS), d (ppm): 1.000-1.126 (s, –CH3 b), 1.209 (t, N-
CH3, 12H), 3.260-3.549 (m, –O-CH2-CH2- a), 3.641 (d, N-CH2, 8H),
6.980 (m, H2-H7-H4-H5, 4H), 7.094 (d, H8-H1, 2H), 7.473 (dd, H60,
1H), 7.842 (m, H40-H50, 2H), 8.320 (dd, H30, 1H).
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Unloaded and NCL-loaded Pluronic1 mixed micelles (PMM)
were prepared by thin-ﬁlm hydration method (Zhang et al., 1996).
Brieﬂy, different amounts of a P123/F127 mixture (2:1 w/w) were
dissolved in ethanol in a round-bottom ﬂask to give solutions at
different concentrations (10–50 mg mL1). For drug-loaded
micelles, different amounts of NCL (0.1–1.0 mg mL1) were
dissolved in ethanol and added to Pluronic1 solution. Then, the
solvent was removed by rotary evaporation at 50 C for about
20 min. After that, the dried ﬁlm was hydrated with ﬁltered
distilled water and the sample was sonicated for 5 min. Micelle
dispersion was ﬁltered through Phenex1-RC 0.22 mm ﬁlters
(Phenomenex, Italy) to remove the unincorporated drug or
possible large cylindrical aggregates formed by P123. When
necessary, the resulting solution was freeze-dried for 24 h.
For Biotin-decorated PMM (Bio-PMM), biotin-conjugated F127
(20% of total F127 wt) was employed. For Rhodamine B-tagged
PMM (Rho-PMM or Bio/Rho-PMM) rhodaminated-P123 (1% of
total P123 wt) was used to give rhodamine B concentration of
5.0 mM. In the case of Bio/Rho-PMM micelles at 10 mg mL1, for
example, 2.66 mg of F127 and 0.66 mg of biotin-conjugated F127,
6.60 mg of P123 and 0.066 mg of rhodamine B-conjugated P123 (a
stock solution in ethanol of all the components) were used.
Recovery yield of the production process was evaluated on an
aliquot of PMM dispersion by weighting the solid residue after
freeze-drying. Results are expressed as the ratio of actual weight to
the theoretical polymer weight  100. Formulation optimization
was assessed on the basis of micelle size, polydispersity index and
NCL encapsulation efﬁciency.
2.4. Micelle characterization
Hydrodynamic diameter (DH), polydispersity index (PI) and
zeta potential of micelles were determined using a Zetasizer Nano
ZS (Malvern Instruments Ltd., UK). The freeze-dried formulations
were dispersed in Milli-Q water and measurements were
performed at 37.0 C on 90 angle. Results are reported as mean
of three separated measurements on three different micelle
batches (n = 9)  standard deviation (SD). Bio/Rho-PMM morphol-
ogy was evaluated by Transmission Electron Microscopy (TEM,
JEOL JEM-1400, Jeol Ltd.-Japan) after negative staining with a 2%
phosphotungstic acid solution.
The critical micelle concentration (CMC) of the Pluronic1
mixture in aqueous PBS solutions was determined by ﬂuorescence
measurements using pyrene as ﬂuorescent probe (Kalyanasun-
daram and Thomas, 1977). An aliquot (5 mL) of a pyrene stock
solution in acetone (3.6  10–4mol L1) was added into a series of
test tubes, and the acetone was evaporated. Following this, micelle
solutions at various concentrations (3.0 mL) were added to each
test tube and sonicated for 2 h ([pyrene] = 6.0  107mol L1). The
excitation spectra were recorded (from 200 nm to 360 nm) with
the emission wavelength ﬁxed at 372 nm. The CMC was deter-
mined by I337/I334 intensity ratios from excitation spectra of
pyrene.
The amount of biotin available on the surface of Bio-PMM was
quantiﬁed by a competitive binding assay (HABA/avidin) (Bian
et al., 2012). Rhodamine B-conjugated P123 was not included in the
micelles to avoid interference in HABA/Avidin complex absorption.
The powdered HABA/avidin reagent was reconstituted with 10 mL
of deionized water. Thereafter, 900 mL of HABA/avidin solution
were poured into a 1 mL cuvette. The absorption spectrum from
450 nm to 700 nm was collected and the absorbance at l = 500 nm
was recorded and indicated as A500HABA/Avid. Then, 100 mL of Bio-
PMM were added into this solution. After extensive mixing, theabsorbance at l = 500 nm was recorded and indicated as
AHABA=Avidþsample500 . The absorbance of the blank micelle solution at
l = 500 nm was indicated as Ablanksample500 .
The amount of the biotin actually exposed onto micelles was







where DA500 ¼ 0:9  AHABA=Avid500  AHABA=Avidþsample500 . The results are
reported as mean of three separate measurements  SD.
2.5. Niclosamide loading and release
NCL-loading was evaluated by measuring the UV–vis absorp-
tion after diluting the freshly prepared NCL-loaded PMM
formulations in ethanol (1:100 v/v).
In vitro release of NCL from micelles was assessed by a dialysis
method. A known amount of NCL-loaded micelles (40 mg) was
dispersed in 1 mL of PBS or Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) supplemented with 10% of fetal bovine serum (FBS) and
placed in a dialysis bag (MWCO = 3500 Da, Spectra/Por1). The
samples were plunged in 5 mL of 10 mM phosphate buffer at pH 7.4
containing 137 mM NaCl and 2.7 mM KCl (PBS) containing 0.5% v/v
of polysorbate 80 in order to ensure sink conditions and to avoid
NCL precipitation and kept at 37 C. At selected time intervals, 1 mL
of release medium was withdrawn, replaced with an equal volume
of fresh medium and analysed. Release proﬁle of free NCL (0.7 mg
dissolved in 1 mL of ethanol or DMEM with 10% FBS medium) are
reported for comparison. Results are expressed as mean release%
over time (n = 3)  SD.
The amount of NCL in the samples was measured at 331 nm on a
Shimadzu 1800 spectrophotometer (Shimadzu, Italy) in a 1.0 cm
quartz cuvette as previously reported (Costabile et al., 2015).
Brieﬂy, a calibration curve was obtained by plotting absorbance
versus the concentration of NCL standard solutions in ethanol. The
linearity of the response was veriﬁed over a concentration range of
0.2–10 mg/mL (r2 = 0.998). The limit of detection and quantiﬁcation
were 0.24 mg/L and 0.80 mg/L, respectively. Unloaded micelles and
release media had negligible absorption at 331 nm.
2.6. Cell cultures
Adenocarcinoma human alveolar basal epithelial (A549) and
mouse embryo ﬁbroblast (NIH3T3) cell lines were purchased from
American Type Culture Collection (Rockville, MD, USA) and were
authenticated by LGC Standards (Sesto San Giovanni, Italy). A549
and NIH3T3 cells were cultured in DMEM with glutamax
(Invitrogen, Carlsbad, California) supplemented with 10% FBS,
2 mM L-glutamine and penicillin-streptomycin 50 U/ml.
2.7. Micelle uptake by ﬂuorescence microscopy
A549 and NIH3T3 cells were plated on coverslips at a density of
2  104 cells per well in 12-well plates. Then, cells were incubated
with Rho-PMM and Bio/Rho-PMM (0.5 mg/mL) for 1, 4 and 24 h.
Intracellular localization of micelles was monitored using a
ﬂuorescent microscope (Leica Microsystems GmbH, Wetzlar,
Germany) to visualize 40,6-diamidino-2-phenylindole (DAPI)
(345/661 nm) and Rhodamine-labelled micelles (557/571 nm).
Fluorescence images were collected and processed by Axiovision
4.8.1 software. Images were processed, merged and reconstructed
using Adobe Photoshop software. The scale bars on all the images
correspond to 10 mm.
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A cisplatin-resistant A549 cell line (CPr-A549) was generated by
continuously culturing the drug-sensitive parental cell line A549 in
a medium containing increasing concentrations of cisplatin (from
0.5 mM to 14 mM) in a stepwise procedure over 10 months. After 10
months, the selected cells were ‘pooled', in order to avoid clonality,
and were tested to evaluate the rate of drug resistance, calculated
as the resistance index, RI = IC50 CPr-A549/IC50 A549. Both cell lines
were grown in DMEM medium containing 10% heat inactivated
FBS, 50 U/ml penicillin, 500 mg/ml streptomycin, 20 mM Hepes (pH
7.4) and 4 mM glutamine. The cells were grown in a humidiﬁed
atmosphere composed of 95% air and 5% CO2 at 37 C.
2.9. Cell viability assays
For MTT assay, A549, CPr-A549 and NIH3T3 cells were seeded
onto 96-well plates (2  104 cells/well) and incubated with
micelles for 24 and 72 h. Then, cell viability was evaluated as
mitochondrial activity using the MTT assay as previously reported
(Maiolino et al., 2015). The absorbance was measured at 540 nm
using a microplate reader (Labsystems Multiskan, MS).
For sulforhodamine B (SRB) colorimetric assay, cell viability of
A549 and CPr-A549 cells was measured after 96 h of drug
treatment in 96-well plates, as described previously (Milone
et al., 2013).
2.10. Protein extraction and western blotting
Cells were grown and treated as indicated above, collected,
lysed and separated on SDS polyacrylamide electrophoresis gels,
and then proteins were transferred to nitrocellulose membranes
(d’Emmanuele et al., 2015). Western blotting assay was performed
as described previously (De Filippis et al., 2016) using antibodies
anti-rpL3 (Primm, Milan, Italy), anti-p53, anti-p21, anti-LRP and
anti-GAPDH (Santa Cruz Biotechnology, Santa Cruz, California),
anti-ABCG2 (Cell Signaling), anti-MRP1 and anti-MDR1 (Abcam).
2.11. Clonogenic assay
For clonogenic assay, CPr-A549 cells were plated in triplicate at
4 103 in 6-well multidishes. At 10 days, colonies were stained
with 1% methylene blue in 50% ethanol. Percent survival was
normalized to the observed number of colonies generated from
untreated cells.
2.12. Statistical analysis
Error bars represent mean  standard error mean (SEM) from
n = 3 biological replicates. Statistical comparisons were made by
one-way ANOVA followed by Bonferroni’s test for multiple
comparisons. * #P < 0.05, ** ## P < 0.01, *** P < 0.005. P > 0.05
was considered not statistically signiﬁcant.
3. Results
3.1. Pluronic1 functionalized with biotin or rhodamine B: synthesis,
assembling properties and cell uptake
Multifunctional micelles were prepared from F127 and P123
reacted at hydroxyl end groups with biotin as targeting agent or
rhodamine B as ﬂuorescent tag, respectively. 1H NMR spectra of
modiﬁed polymers (Fig. 1A and B) showed the main peaks
corresponding to the PPO (1.0–1.2 ppm) and PEO (3.2–3.6 ppm)
segments. Most of biotin signals were overlapped to polymers
signals (Fig. 1A) although the multiple signals at 4.138 ppm (H60),4.300 ppm (H6) and the singlet signals at 6.363 ppm (HN2) and
6.437 ppm (HN1) conﬁrmed biotin-F127 conjugation. For the
rhodamine-conjugated P123 (Fig. 1B), the aromatic signals above
7 ppm conﬁrm Rhodamine conjugation to P123 molecules.
Suggestion that modiﬁed polymers could self-assemble with
unmodiﬁed ones to form mixed micelles was given by comparing
1H NMR in DMSO-d6 and D2O as solvents. In fact, DMSO-d6 is a
good solvent for all components and signals referring to all the
species could be detected (Fig. 1A and B). Nevertheless, D2O is a
good solvent for biotin, rhodamine B and PEO blocks while
lipophilic PPO blocks are poorly soluble in water, driving the
formation of the micelle core. In fact, NMR signals originating from
hydrophobic PPO blocks were suppressed in water due to PPO
restricted motion in the micelle core (Fig. 1C).
Bio-PMM were prepared at 2:1 (w/w) P123 and F127 ratio on
the basis of our previous study (Pellosi et al., 2016). The CMC of
P123/F127 mixture in the presence of Biotin-conjugated F127 was
0.0031% w/V, as evaluated by pyrene method (Fig. 2A). Analogous-
ly, addition of Rho-conjugated P123 did not alter Bio-PMM
properties (data not shown). The availability of biotin on micelle
surface was also quantiﬁed by measuring the absorbance of the
HABA/avidin complex at 500 nm (Fig. 2B) (Bian et al., 2012). The
theoretical amount of available biotin on Bio-PMM was 1.25 mmol
mL1, corresponding to 10% of biotin at a micelle concentration of
10 mg mL1. The actual available amount of biotin was 1.04 mmol
mL1, which means that approximately 8.3% of the micelle surface
is covered with biotin. Bio-PMM were almost spherical as shown in
the TEM image reported in Fig. 2C.
The uptake and the subcellular distribution of unloaded Rho-
PMM and Bio/Rho-PMM were assessed in biotin receptor-positive
A549 cells and in a non-cancerous cell line NIH3T3 as control. After
a time-dependent incubation with micelles (1, 4 and 24 h), the cells
were stained with DAPI and observed by ﬂuorescence microscopy.
In A549 cells, the large majority of the ﬂuorescence associated to
Bio/Rho-PMM was distributed in the cytoplasm, conﬁrming
micelle internalization (Fig. 3). The quantiﬁcation of ﬂuorescence
revealed a time-dependent uptake of the micelles. In normal
NIH3T3 ﬁbroblasts, a very limited internalization of both Rho-
PMM and Bio/Rho-PMM was found (Fig. 4).
3.2. NCL-loaded PMM: properties and cytotoxicity in A549 cells
Table 1 summarizes the physicochemical characteristics and
drug-loading parameters of NCL-loaded PMM. In each case, PMM
with increased PI and a hydrodynamic diameter within the range
25–35 nm were achieved as compared to unloaded PMM (Table 1).
Zeta potential values were slightly negative independently of the
drug amount loaded (Table 1) as generally found for uncharged
PEO-coated nanocarriers due the high electronic density of oxygen
(Conte et al., 2014). Of note, both micelle size and charge were not
affected by the presence of the small and neutral biotin molecule
on micelle surface at present conditions. The encapsulation
efﬁciency strongly depended upon Pluronic1/NCL ratio by weight.
High ratios resulted in good encapsulation efﬁciencies while the
opposite effect was observed at lower Pluronic1/NCL ratios, likely
due to drug precipitation during preparation. The optimal
formulation condition for NCL encapsulation was at 40 mg mL1
for Pluronic1 mixture and 0.7 mg mL1 for NCL. Blank micelles at
same polymer concentration (control experiment) presented a size
of 29.5 nm (PI = 0.142) and zeta potential of 3.81 mV.
Release proﬁle of NCL from NCL-loaded Bio-PMM in PBS at pH
7.4 was evaluated by dialysis method (Fig. 5). NCL displayed a
biphasic release proﬁle with an initial burst (ﬁrst 6 h) followed by a
sustained release phase lasting up to 48 h. The drug could freely
diffuse through the dialysis membrane as demonstrated in control
experiments. Release proﬁle in the DMEM supplemented with 10%
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slower than in PBS (Fig. 5).
In the light of the promising technological features, we tested
the cytotoxicity of the optimized NCL-loaded micelles in A549Fig. 1. 1H NMR spectra of: (A) biotin-conjugated F127 in DMSO-d6; (B) rhcancer cells and normal NIH3T3 ﬁbroblasts. To this aim,
cytotoxicity of NCL-loaded micelles incubated in a wide range of
concentrations (1.3–112 mg mL1 corresponding to 0.07–6 mM ofodamine B-conjugated P123 in DMSO-d6; (C) Bio/Rho-PMM in D2O.
Fig. 3. Fluorescence microscopy images of A549 cells after incubation with Rho-tagged micelles. A549 cells were incubated with Rho-PMM and Bio/Rho-PMM (0.5 mg/mL) for
1, 4 and 24 h. Cell nuclei were stained with DAPI. Fluorescence images were collected and processed by Axiovision 4.8.1 software. All measurements were normalized to the
ﬂuorescence of Bio/Rho-PMM in cell medium set as 100%. Bars represent mean values  SEM of experiments done in triplicate. *P < 0.05, ***P < 0.005.
Fig. 2. Properties of Bio-PMM. (A) Fluorescence excitation spectra of pyrene (6.0  107mol L1) as a function of the concentration of Bio-PMM in PBS at pH 7.4 and 37 C. The
inset shows the plot of the intensity ratio (I337/I334) from the ﬂuorescence excitation spectra of pyrene at 372 nm as a function of logarithm concentration of PMM. (B) UV–vis
spectra of the HABA/Avidin complex and HABA/Avidin complex after Bio-PMM addition. (C) TEM image of Bio/Rho-PMM.
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Fig. 4. Fluorescence microscopy images of NIH3T3 cells after incubation with Rho-tagged micelles. NIH3T3 cells were incubated with Rho-PMM and Bio/Rho-PMM (0.5 mg/
mL) for 1, 4 and 24 h. Cell nuclei were stained with DAPI. Fluorescence images were collected and processed by Axiovision 4.8.1 software. All measurements were normalized
to the ﬂuorescence of Bio/Rho-PMM in cell medium set as 100%. Bars represent mean values  SEM of experiments done in triplicate.
Table 1













10 0.1 100 95 0.913  0.043
(91.5  1.2)
27.4  1.8 0.132 3.91  0.67
10 0.2 50 89 1.33  0.10
(67.8  1.8)
35.9  2.4 0.266 4.59  1.15
10 0.3 33 89 1.72  0.26
(59.0  3.1)
28.2  4.7 0.345 3.33  1.89
20 0.1 200 92 0.495  0.014
(99.2  1.2)
25.2  1.2 0.138 4.01  0.88
20 0.3 67 85 1.24  0.052
(88.4  3.4)
24.2  2.3 0.178 3.89  1.01
20 0.5 40 91 1.62  0.073
(66.4  4.1)
20.2  3.7 0.351 5.49  2.48
30 0.5 60 90 1.54  0.38
(93.9  2.0)
28.4  2.5 0.152 4.62  1.61
40 0.7 57 94 1.58  0.55
(91.9  1.9)
31.8  1.7 0.131 3.37  1.08
50 0.7 71 88 1.29  0.27
(93.4  4.1)
26.5  2.5 0.129 5.49  2.07
50 1.0 50 93 1.81  0.49
(92.3  4.1)
33.4  3.9 0.246 2.21  0.88
a P123/F127 mixture 2:1 w/w where biotin-conjugated F127 was used at 20% of F127 mass.
b Actual loading is expressed as the amount (mg) of drug encapsulated per 100 mg of Bio-PMM SD.
c Entrapment efﬁciency (EE) is expressed as the ratio between experimental and theoretical NCL loading  100 SD.
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compared to that of free NCL (Fig. 6).
Results indicated that NCL-loaded Bio-PMM micelles were
signiﬁcantly more cytotoxic than NCL and NCL-loaded PMM in
A549 cells (Fig. 6A). No signiﬁcant difference in cytotoxicity
between free NCL and NCL-loaded micelles was found in NIH3T3.
Unloaded PMM and Bio-PMM did not show any cytotoxicity toward
both cell lines at any concentration tested (Fig. S1, Supplementary
material). Data from MTT at 24 h highlight that cytotoxicity wasagain signiﬁcantly higher for NCL-loaded Bio-PMM (Fig. S2,
Supplementary material).
3.3. In vitro activity of NCL-loaded PMM against resistant lung cancer
cells
A cisplatin-resistant subline derived from the parental sensitive
cell line A549 was successfully established. A549 cells were
continuously selected with cisplatin over a period of 10 months in

















 NCL Bio-PMM  in  PBS
 NCL in  PBS
 NCL Bio-PMM  in  DMEM
 NCL in  DMEM
Fig. 5. Release proﬁles of NCL and NCL-loaded Bio-PMM dispersed in PBS and in
DMEM supplemented with FBS 10%. Free NCL is reported as control. The external
medium used for dialysis was PBS with polysorbate 80 (0.5% v/v) at pH 7.4 and at
37 C. NCL concentration in the bag was 0.7 mg mL1. Data are reported as mean of
three independent experiments (n = 3) SD.
Fig. 6. In vitro cytotoxicity of free NCL and NCL-loaded micelles toward A549 (A)
and NIH3T3 (B) cells. The cells were exposed to increasing concentrations of PMM
(1.3–112 mg mL1 corresponding to 0.07–6 mM of NCL) or NCL in DMSO (0.07–6 mM)
for 72 h. After incubation, cell viability was evaluated using the MTT assay. The cell
viability from untreated cells was set to 100%. Results are presented as percentage
(mean  SEM) (n = 3) of the control cells. *, ** NCL-loaded Bio-PMM vs NCL-loaded
PMM. #,## NCL-loaded Bio-PMM vs NCL. * #P < 0.05, ** ##P < 0.01.
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cisplatin-resistant cell line, designated as CPr-A549. Maintenance
of the resistant subline was continued at 14 mM. The SRBproliferation assay demonstrated an increased resistance to
cisplatin-induced cell death (Fig. 7A). Speciﬁcally, the drug-
adapted CPr-A549 cell line showed a signiﬁcantly higher IC50
compared with parental A459 cells (13.3  4 versus 3.8  0.4,
respectively; P <0.05), resulting in more than 3-fold resistance to
cisplatin (Table 2). In addition, we demonstrated a signiﬁcant
increase in the IC50 of CPr-A549 cells compared to A549 cells
(Table 2) to other conventional chemotherapeutic drugs such as
docetaxel (Fig. 7B), 50-deoxy-5-ﬂuorouridine (50-DFUR) (Fig. 7C)
and 5-ﬂuorouracil (5-FU) (Fig. 7D). These results indicate that CPr-
A549 cells show resistance to multiple drugs representing an
interesting tool to study MDR in lung cancer.
The effect of free NCL on CPr-A549 cell line viability was ﬁrst
investigated. To this purpose, cells were exposed to a wide range of
NCL concentrations (ranging from 0.07 to 6 mM) and in vitro
cytotoxicity evaluated by using MTT assay. Fig. 8A shows the dose-
response effect after 72 h of treatment with free NCL giving an IC50
value of 1.8 mM. This result demonstrated that NCL can overcome
resistance to different chemotherapeutics in CPr-A549 cells.
To go in depth into molecular mechanism underlying MDR in
Crp-A549 cells, the expression proﬁle of ATP binding cassette (ABC)
efﬂux pumps ABCG2, lipoprotein receptor-related protein (LRP)
was evaluated. The expression level of multi-drug resistance 1/P-
glycoprotein (MDR1) and MDR-associated protein 1 (MRP1) was
also analyzed. Western blotting analysis showed no difference in
the expression of such proteins in CPr-A549 cells as compared with
the parental A549 cells (Fig. 8B).
To investigate whether NCL cytotoxic effect on CPr-A549 cells
was associated to nucleolar stress, protein extracts from CPr-A549
cells treated or not with free NCL were analyzed by western
blotting for the expression proﬁle of rpL3 and its target p21 protein.
We found that the resistance of A549 cells to cisplatin correlated to
the loss of rpL3 expression (Fig. 8C). NCL treatment caused a
signiﬁcant increase of rpL3 level that was associated to the up-
regulation of p21.
The antiproliferative activity of NCL-loaded micelles towards
multidrug-resistant CPr-A549 cancer cells was ﬁnally investigated
(Fig. 9). After 3 days of treatment, in vitro cytotoxicity was ﬁrst
evaluated by MTT assay. Extrapolation from the dose-response
curve demonstrated that cytotoxicity of NCL-loaded Bio-PMM was
higher than that of NCL-loaded PMM (and free NCL) depending on
the dose (Fig. 9A). To exclude deﬁnitively that treated cells retained
any capacity to divide and to proliferate, the in vitro effectiveness of
NCL-loaded Bio-PMM against CPr-A549 cells was also assessed
through a clonogenic assay. The assay was performed after
treatment of CPr-A549 cells with 0.3, 0.9 and 1.8 mM of NCL-
loaded Bio-PMM for 72 h. As can be seen in Fig. 9B, after 10 days the
colony number was strongly reduced upon exposure to drug-
loaded Bio-PMM conﬁrming the ability of NCL to inhibit
clonogenicity.
4. Discussion
An increasing resistance of cancer cells to the treatment with
commonly used chemotherapeutic drugs has raised the urgency in
the search for new anti-cancer agents. Several drugs originally
approved for indications other than cancer therapy have recently
been found to exert a cytotoxic effect on cancer cells (Shim and Liu,
2014; Stenvang et al., 2013). Cisplatin represents the ﬁrst line
chemotherapy for the treatment of a variety of tumors, including
non-small cells lung cancer (NSCLC), and platinum resistance is a
major limitation in the treatment of NSCLC. Recent studies
focusing on the anthelmintic drug NCL demonstrate its ability to
overcome drug resistance in different cancers (Li et al., 2013; Liu
et al., 2015, 2014).
Fig. 7. Development of cisplatin-resistant NSCLC cell line. Sensitive A549 cells and CPr-A549 cells were treated with increasing concentrations of (A) Cisplatin, (B) Docetaxel,
(C) 5-FU or (D) 50-DFUR for 96 h and cell growth assessed by SRB colorimetric assay. Cell growth is expressed as percentage of control for each time point. Values are the
mean  SD from at least three independent experiments performed in quadruplicates. *P < 0.05, **P < 0.01.
Table 2
Antiproliferative effect of anticancer drugs on sensitive A549 and cisplatin-resistant
A549 cells (CPr-A549). Resistance index (RI) is reported as IC50 CPr-A549/IC50 A549.
IC50 (mM)
A549 CPr-A549
Cisplatin 3.8  0.4 13.3  4 (RI = 3.5)
Docetaxel 0.54 103 0.05 103 > 64 103 (RI > 164)
5-FU 2.55  0.07 8.9  0.28 (RI = 3.45)
50-DFUR 4.65  0.35 17.98  3.7 (RI = 3.97)
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in vivo runs into special difﬁculties, mainly related to the very poor
solubility proﬁle of NCL in biological ﬂuids. To overcome NCL
solubility constraints, Pluronic1 P123/F127 mixed micelles (PMM)
for targeted delivery of NCL to lung cancer cells were built up.
In a previous work, we demonstrated that PMM made of 2:1 (w/
w) mixtures of P123 and F127 display high stability to dilution and
can load highly hydrophobic benzoporphyrin derivatives (Pellosi
et al., 2016) . Here, PMM were surface-engineered to encourage cell
internalization by exposing biotin on their surface. PMM were also
made ﬂuorescent by linking Rhodamine B to micelle surface to
track their trafﬁcking inside cells. Biotin and rhodamine B were
linked to Pluronic1 unimers at their hydroxyl-termination using
carbodiimide chemistry (Li et al., 2010). We decided to conjugatebiotin to F127, bearing longer PEO blocks, while rhodamine B was
linked to P123, with shorter PEO chains. Through this design, it was
expected that targeting ligand exposition on micelle surface is
attained and any interference between biotin and rhodamine is
minimized, which is a key prerequisite for micelle-receptor
recognition. NMR analyses provided insight into the occurrence
of the self-assembly of the two Pluronic derivatives, indicating the
formation of a well-deﬁned core-shell structure in aqueous
solution where a “water-protected” PPO core is surrounded by a
PEO hydrophilic coating exposing biotin as targeting element and
rhodamine B as ﬂuorescent tag. Indeed, complex formation of Bio-
PMM with avidin clearly indicates that biotin was surface-exposed
and potentially able to interact with receptors on cell membranes
(Bian et al., 2012). Meanwhile, the reasonably low CMC value
indicated a good stability of targeted PMM to dilution being
promising for their potential applications as drug carrier.
Aiming at demonstrating the soundness of this approach to
promote NCL accumulation in cancer cells, the uptake and the
subcellular distribution of unloaded Rho-PMM and Bio/Rho-PMM
were assessed in biotin receptor-positive lung A549 cancer cells
and in a non-cancerous NIH3T3 cell line. Results demonstrated a
higher amount of biotin-decorated PMM in cancer cells as
compared to normal cells. Thus, the overexpression of biotin
receptors on the surface of A549 cancer cells relative to normal
NIH3T3 cells, induced a higher micelle uptake by receptor-
Fig. 8. Effect of NCL in CPr-A549 cells. (A) In vitro cytotoxicity of NCL (0.07–6 mM) toward CPr-A549 cells after 72 h. Cell viability was evaluated by MTT assay. The cell viability
from untreated cells was set to 100%. Results are presented as percentage (mean  SEM) (n = 3) of the control cells. *P < 0.05, ** P < 0.01. (B) Expression proﬁle of MRD1, ABCG2,
MRP1 and LRP, in Cpr-A549 cells. Protein extracts from A549 cells (control) and CPr-A549 cells were analysed by western blotting by using anti- MRD1, anti-ABCG2, anti-
MRP1, anti-LRP and anti-GAPDH to normalize. (C) Analysis of rpL3 and p21 expression upon NCL treatment in Cpr-A549 cells. Protein extracts from A549 cells (control) and
Cpr-A549 cells, untreated or treated with free NCL, were analysed by western blotting by using anti-rpL3, anti-p21 and anti-b-actin to normalize results. Quantiﬁcation of
signals is shown. Bars represent mean values  SEM of experiments done in triplicate. ***P < 0.005.
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et al., 2013).
The feasibility of the proposed approach for selective delivery of
NCL in lung cancer cells was then assessed. To this purpose,
preliminary studies were devoted to the development of Bio-PMM,
affording high encapsulation efﬁciency of NCL at the minimum
Pluronic1/NCL ratio (i.e. higher drug loading for micelle). The keyfactor for formulation optimization was the dependence of the
encapsulation efﬁciency on Pluronic/NCL weight ratio. Values
between 50 and 60 were considered suitable for a therapeutically-
relevant system. Besides a slight size increase after entrapment of
the drug, likely ascribable to drug entangling in the PPO core, the
micelles were still small enough for tumor-speciﬁc accumulation
via the EPR effect (Batrakova and Kabanov, 2008). Furthermore, the
Fig. 9. In vitro cytotoxicity of NCL-loaded micelles in CPr-A549 cells. (A) CPr-A549 cells were exposed to increasing concentrations of micelles (1.3–112 mg mL1
corresponding to 0.07–6 mM of NCL) for 72 h. After incubation, cell viability was evaluated by MTT assay. Cytotoxicity of NCL from Fig. 8 is reported to facilitate comparison.
The cell viability from untreated cells was set to 100%. Results are presented as percentage (mean  SEM) (n = 3) of the control cells. * P < 0.05, *** P < 0.005. (B) Clonogenic
assay on CPr-A549 cells treated with 0.3, 0.9 and 1.8 mM of NCL for 72 h or untreated. After 10 days, colonies were stained with methylene blue, counted and photographed. Bar
chart indicating clonogenic growth is shown. *P < 0.05, **P < 0.01, *** P < 0.005.
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in a complex protein-rich milieu, such as the cell culture medium
employed for in vitro experiments.
Prompted by these encouraging ﬁndings, the in vitro anti-
proliferative effect of the selected NCL-loaded Bio-PMM was
investigated in lung cancer cells, as well as in normal cells. NCL-
loaded Bio-PMM displayed an enhanced cytotoxic activity in A549
cells as compared to healthy cells, which correlated well with their
higher intracytoplasmic accumulation.
For a better understanding of the therapeutic potential of NCL-
loaded Bio-PMM and to investigate the molecular basis of NCL
cytotoxic activity, we successfully established a cisplatin-resistant
lung cancer subline derived from the parental sensitive cell line
A549 (CPr-A549 cells), which demonstrated resistance also to
other conventional chemotherapeutics. Drug resistance may bedue to decreased inﬂux or increased efﬂux of drugs (Rabik and
Dolan, 2007). Several ABC transporter efﬂux inhibitors have been
described (Schinkel and Jonker, 2003) and it is well established
that the transmembrane ATP binding cassette (ABC) efﬂux pumps
ABCB1 (P-glycoprotein, P-gp), ABCC1 (MDR-associated protein 1,
MRP1), and ABCG2 (breast cancer resistance protein, BCRP) play a
crucial role in the development of drug resistance (Eckford and
Sharom, 2009). Our results clearly indicate that the development
of MDR in CPr-A549 cells was not the result of the overexpression
of neither ABCG2 and LRP, nor MDR1 and MRP1 suggesting the
involvement of other pathways.
Recently our studies focused on the extraribosomal functions of
ribosomal proteins (Russo et al., 2011, 2010), with particular
attention to their role in chemotherapy and chemoresistance
(Pagliara et al., 2016). Speciﬁcally, we demonstrated that
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stress induced by anticancer drugs such as 5-Fluorouracil (5-FU),
Actinomycin D and oxaliplatin (Esposito et al., 2014; Russo et al.,
2016). In fact, upon drug-induced nucleolar stress, free rpL3 is able
to induce cell cycle arrest, apoptosis and to inhibit cell proliferation
and migration by controlling p21 expression both at post-
transcriptional and post-translational levels. Furthermore, we
demonstrated that rpL3 status was associated to chemoresistance
since the loss of rpL3 makes the tested chemotherapeutic drugs
ineffective (Esposito et al., 2014; Russo et al., 2016). In agreement
with our previous results, CPr-A549 cells resistance to cisplatin
correlated to the loss of rpL3 expression. It is noteworthy that NCL
caused a signiﬁcant increase of rpL3 level that was associated to
the up-regulation of p21. These data reveal that a novel molecular
mechanism implicated in the cytotoxic activity of NCL can be
hypothesized, involving nucleolar stress and rpL3/p21 response
pathway.
Of note, results on CPr-A549 cells demonstrated not only that
NCL is still active in resistant lung cancer cells but also that biotin-
targeted PMM maintain their cytotoxicity proﬁle being more
cytotoxic than non-targeted micelles, especially at low concen-
trations. These results point at biotin-decorated PMM as a
reasonable strategy to improve NCL activity also in resistant lung
cancer cells, which, after treatment, become deﬁnitively unable to
divide and to proliferate.
5. Conclusions
With this study we demonstrate that NCL delivered through
tailored Pluronic1 mixed micelles can be a valuable therapeutic
tool in the treatment of multi-drug resistant NSCLC. Biotin-
targeted Pluronic mixed micelles designed for intravenous
injection entrapped NCL with good yield, showed sustained NCL
release and were stable in protein-rich media. As compared to
normal NIH3T3 ﬁbroblasts, biotin-targeted micelles were inter-
nalized much more efﬁciently and exerted a more potent
cytotoxicity than that of both free NCL and non-targeted micelles
in A549 cells. After selecting a resistant A549 cell line, we
identiﬁed rpL3 and p21 as new molecular targets of NCL and
demonstrated that the activation of rpL3/p21 pathway by NCL
overcomes MDR. Superior cytotoxicity of NCL-loaded biotin-
targeted micelles was clearly evidenced in A549 cell resistant to
cisplatin, 5-FU and docetaxel while the clonogenic assay demon-
strated that, after treatment, cells becomes unable to divide and to
proliferate. Taken all together, these results demonstrate that a
NCL-based regimen with biotin-decorated Pluronic micelles might
be a promising second-line chemotherapy for lung cancer showing
cisplatin or multi-drug resistance.
Conﬂicts of interest
All authors declare no conﬂicts of interest.
Acknowledgments
F.Q. and G.R. wish to thank the Italian Ministry of University and
Research (PRIN 2010H834LS, PRIN20104AE23N_006). F.Q. wishes
also to thank Italian Association for Cancer Research (IG2014,
#15764) for ﬁnancial support. F.U. gratefully acknowledges
Compagnia di San Paolo and Istituto Banco di Napoli—Fondazione
(STAR Program, Junior Principal Investigator Grant 2013, Napoli_-
call2013_35) for ﬁnancial support.
D.S.P and N.H. wishes to thank the Brazilian agency Coorde-
nação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
process number BEX 14036/13-14.Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
ijpharm.2016.06.118.
References
Alakhova, D.Y., Kabanov, A.V., 2014. Pluronics and MDR reversal: an update. Mol.
Pharm. 11, 2566–2578.
Alvarez-Lorenzo, C., Sosnik, A., Concheiro, A., 2011. PEO-PPO block copolymers for
passive micellar targeting and overcoming multidrug resistance in cancer
therapy. Curr. Drug Targets 12, 1112–1130.
Ashburn, T.T., Thor, K.B., 2004. Drug repositioning: identifying and developing new
uses for existing drugs. Nat. Rev. Drug Discov. 3, 673–683.
Balgi, A.D., Fonseca, B.D., Donohue, E., Tsang, T.C., Lajoie, P., Proud, C.G., Nabi, I.R.,
Roberge, M., 2009. Screen for chemical modulators of autophagy reveals novel
therapeutic inhibitors of mTORC1 signaling. PLoS One 4, e7124.
Batrakova, E.V., Kabanov, A.V., 2008. Pluronic block copolymers: evolution of drug
delivery concept from inert nanocarriers to biological response modiﬁers. J.
Control Release 130, 98–106.
Bian, Q., Xiao, Y., Lang, M., 2012. Thermoresponsive biotinylated star amphiphilic
block copolymer: synthesis self-assembly, and speciﬁc target recognition.
Polymer 53, 1684–1693.
Chen, S., Zhao, X., Chen, J., Chen, J., Kuznetsova, L., Wong, S.S., Ojima, I., 2010.
Mechanism-based tumor-targeting drug delivery system: validation of efﬁcient
vitamin receptor-mediated endocytosis and drug release. Bioconjug. Chem. 21,
979–987.
Conte, C., d’Angelo, I., Miro, A., Ungaro, F., Quaglia, F., 2014. PEGylated polyester-
based nanoncologicals. Curr. Top. Med. Chem. 14, 1097–1114.
Costabile, G., d’Angelo, I., Rampioni, G., Bondi, R., Pompili, B., Ascenzioni, F.,
Mitidieri, E., d’Emmanuele d, V., Sorrentino, R., Miro, A., Quaglia, F., Imperi, F.,
Leoni, L., Ungaro, F., 2015. Toward repositioning niclosamide for antivirulence
therapy of pseudomonas aeruginosa lung infections: development of inhalable
formulations through nanosuspension technology. Mol. Pharm. 12, 2604–2617.
De Filippis, D., Russo, A., De Stefano, D., Cipriano, M., Esposito, D., Grassia, G.,
Carnuccio, R., Russo, G., Iuvone, T., 2016. Palmitoylethanolamide inhibits rMCP-
5 expression by regulating MITF activation in rat chronic granulomatous
inﬂammation. Eur. J. Pharmacol. 725, 64–69.
Ding, H., Yong, K.T., Law, W.C., Roy, I., Hu, R., Wu, F., Zhao, W., Huang, K., Erogbogbo,
F., Bergey, E.J., Prasad, P.N., 2011. Non-invasive tumor detection in small animals
using novel functional Pluronic nanomicelles conjugated with anti-mesothelin
antibody. Nanoscale 3, 1813–1822.
Eckford, P.D., Sharom, F.J., 2009. ABC efﬂux pump-based resistance to chemotherapy
drugs. Chem. Rev. 109, 2989–3011.
Esposito, D., Crescenzi, E., Sagar, V., Loreni, F., Russo, A., Russo, G., 2014. 2014: human
rpL3 plays a crucial role in cell response to nucleolar stress induced by 5-FU and
L-OHP. Oncotarget 5, 11737–11751.
Heo, D.N., Yang, D.H., Moon, H.J., Lee, J.B., Bae, M.S., Lee, S.C., Lee, W.J., Sun, I.C., Kwon,
I.K., 2012. Gold nanoparticles surface-functionalized with paclitaxel drug and
biotin receptor as theranostic agents for cancer therapy. Biomaterials 33, 856–
866.
Jung, Y.W., Lee, H., Kim, J.Y., Koo, E.J., Oh, K.S., Yuk, S.H., 2013. Pluronic-based core/
shell nanoparticles for drug delivery and diagnosis. Curr. Med. Chem. 20, 3488–
3499.
Jung, D., Maiti, S., Lee, J.H., Lee, J.H., Kim, J.S., 2014. Rational design of biotin-
disulﬁde-coumarin conjugates: a cancer targeted thiol probe and bioimaging.
Chem. Commun. (Camb.) 50, 3044–3047.
Kabanov, A.V., Batrakova, E.V., Alakhov, V.Y., 2002. Pluronic block copolymers as
novel polymer therapeutics for drug and gene delivery. J. Control Release 82,
189–212.
Kalyanasundaram, K., Thomas, J.K., 1977. Environmental effects on vibronic band
intensities in pyrene monomer ﬂuorescence and their application in studies of
micellar systems. J. Am. Chem. Soc. 99, 2039–2044.
Li, Z.L., Xiong, X.Y., Li, Y.P., Gong, Y.C., Gui, X.X., Ou-Yang, X., Lin, H.S., Zhu, L.J., Xie, J.L.,
2010. Synthesis and self-assembling behaviors of biotinylated pluronic/poly
(lactic acid) biocompatible block copolymers in aqueous solutions. J. Appl.
Polym. Sci. 115, 1573–1580.
Li, R., Hu, Z., Sun, S.Y., Chen, Z.G., Owonikoko, T.K., Sica, G.L., Ramalingam, S.S.,
Curran, W.J., Khuri, F.R., Deng, X., 2013. Niclosamide overcomes acquired
resistance to erlotinib through suppression of STAT3 in non-small cell lung
cancer. Mol. Cancer Ther. 12, 2200–2212.
Li, Y., Li, P.K., Roberts, M.J., Arend, R.C., Samant, R.S., Buchsbaum, D.J., 2014. Multi-
targeted therapy of cancer by niclosamide: a new application for an old drug.
Cancer Lett. 349, 8–14.
Liu, C., Lou, W., Zhu, Y., Nadiminty, N., Schwartz, C.T., Evans, C.P., Gao, A.C., 2014.
Niclosamide inhibits androgen receptor variants expression and overcomes
enzalutamide resistance in castration-resistant prostate cancer. Clin. Cancer
Res. 20, 3198–3210.
Liu, C., Lou, W., Armstrong, C., Zhu, Y., Evans, C.P., Gao, A.C., 2015. Niclosamide
suppresses cell migration and invasion in enzalutamide resistant prostate
cancer cells via Stat3-AR axis inhibition. Prostate 75, 1341–1353.
Maiolino, S., Russo, A., Pagliara, V., Conte, C., Ungaro, F., Russo, G., Quaglia, F., 2015.
Biodegradable nanoparticles sequentially decorated with Polyethyleneimine
A. Russo et al. / International Journal of Pharmaceutics 511 (2016) 127–139 139and Hyaluronan for the targeted delivery of docetaxel to airway cancer cells. J.
Nanobiotechnol. 13, 29.
Maiti, S., Park, N., Han, J.H., Jeon, H.M., Lee, J.H., Bhuniya, S., Kang, C., Kim, J.S., 2013.
Gemcitabine-coumarin-biotin conjugates: a target speciﬁc theranostic
anticancer prodrug. J. Am. Chem. Soc. 135, 4567–4572.
Milone, M.R., Pucci, B., Bruzzese, F., Carbone, C., Piro, G., Costantini, S., Capone, F.,
Leone, A., Di Gennaro, E., Caraglia, M., Budillon, A., 2013. Acquired resistance to
zoledronic acid and the parallel acquisition of an aggressive phenotype are
mediated by p38-MAP kinase activation in prostate cancer cells. Cell. Death Dis.
4, e641.
Morral-Ruiz, G., Melgar-Lesmes, P., Lopez-Vicente, A., Solans, C., Garcia-Celma, M.,
2015. Biotinylated polyurethane-urea nanoparticles for targeted theranostics in
human hepatocellular carcinoma. Nano Res. 8, 1729–1745.
Novac, N., 2013. Challenges and opportunities of drug repositioning. Trends
Pharmacol. Sci. 34, 267–272.
Pellosi, D.S., Tessaro, A.L., Moret, F., Gaio, E., Reddi, E., Caetano, W., Quaglia, F., Hioka,
N., 2016. Pluronic-« mixed micelles as efﬁcient nanocarriers for benzoporphyrin
derivatives applied to photodynamic therapy in cancer cells. J. Photochem.
Photobiol. A: Chem. 314, 143–154.
Pagliara, V., Saide, A., Mitidieri, E., d’Emmanuele di Villa Bianca, R., Sorrentino, R.,
Russo, G., Russo, A., 2016. 5-FU targets rp to induce mitochondrial apoptosis via
cystathionine-’-synthase in colon cancer cells lacking p53. Oncotarget doi:
http://dx.doi.org/10.18632/oncotarget.10385.
Rabik, C.A., Dolan, M.E., 2007. Molecular mechanisms of resistance and toxicity
associated with platinating agents. Cancer Treat. Rev. 33, 9–23.
Ren, X., Duan, L., He, Q., Zhang, Z., Zhou, Y., Wu, D., Pan, J., Pei, D., Ding, K., 2010.
Identiﬁcation of niclosamide as a new small-molecule inhibitor of the STAT3
signaling pathway. ACS Med. Chem. Lett. 1, 454–459.
Russo, A., Siciliano, G., Catillo, M., Giangrande, C., Amoresano, A., Pucci, P.,
Pietropaolo, C., Russo, G., 2010. hnRNP H1 and intronic G runs in the splicing
control of the human rpL3 gene. Biochim. Biophys. Acta 1799, 419–428.
Russo, A., Catillo, M., Esposito, D., Briata, P., Pietropaolo, C., Russo, G., 2011.
Autoregulatory circuit of human rpL3 expression requires hnRNP H1 NPM and
KHSRP. Nucleic Acids Res. 39, 7576–7585.
Russo, A., Pagliara, V., Albano, F., Esposito, D., Sagar, V., Loreni, F., Irace, C.,
Santamaria, R., Russo, G., 2016. Regulatory role of rpL3 in cell response to
nucleolar stress induced by Act D in tumor cells lacking functional p53. Cell
Cycle 15, 41–51.
Sack, U., Walther, W., Scudiero, D., Selby, M., Kobelt, D., Lemm, M., Fichtner, I., Schlag,
P.M., Shoemaker, R.H., Stein, U., 2011. Novel effect of antihelminthic niclosamide
on S100A4-mediated metastatic progression in colon cancer. J. Natl. Cancer Inst.
103, 1018–1036.
Schinkel, A.H., Jonker, J.W., 2003. Mammalian drug efﬂux transporters of the ATP
binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55, 3–29.Shim, J.S., Liu, J.O., 2014. Recent advances in drug repositioning for the discovery of
new anticancer drugs. Int. J. Biol. Sci. 10, 654–663.
Siegel, R.L., Miller, K.D., Jemal, A., 2015. Cancer statistics, 2015. CA Cancer J. Clin. 65,
5–29.
Staud, F., Pavek, P., 2005. Breast cancer resistance protein (BCRP/ABCG2). Int. J.
Biochem. Cell Biol. 37, 720–725.
Stenvang, J., Kumler, I., Nygard, S.B., Smith, D.H., Nielsen, D., Brunner, N., Moreira, J.
M., 2013. Biomarker-guided repurposing of chemotherapeutic drugs for cancer
therapy: a novel strategy in drug development. Front. Oncol. 3, 313.
Strouse, J.J., Ivnitski-Steele, I., Waller, A., Young, S.M., Perez, D., Evangelisti, A.M.,
Ursu, O., Bologa, C.G., Carter, M.B., Salas, V.M., Tegos, G., Larson, R.S., Oprea, T.I.,
Edwards, B.S., Sklar, L.A., 2013. Fluorescent substrates for ﬂow cytometric
evaluation of efﬂux inhibition in ABCB1 ABCC1, and ABCG2 transporters. Anal.
Biochem. 437, 77–87.
Stylianopoulos, T., Jain, R.K., 2015. Design considerations for nanotherapeutics in
oncology. Nanomedicine 11, 1893–1907.
Wang, W., Ke, S., Chen, G., Gao, Q., Wu, S., Wang, S., Zhou, J., Yang, X., Lu, Y., Ma, D.,
2004. Effect of lung resistance-related protein on the resistance to cisplatin in
human ovarian cancer cell lines. Oncol. Rep. 12, 1365–1370.
Wang, Y., Zhou, K., Huang, G., Hensley, C., Huang, X., Ma, X., Zhao, T., Sumer, B.D.,
DeBerardinis, R.J., Gao, J., 2014. A nanoparticle-based strategy for the imaging of
a broad range of tumours by nonlinear ampliﬁcation of microenvironment
signals. Nat. Mater. 13, 204–212.
Xiang, D., Yuan, Y., Chen, L., Liu, X., Belani, C., Cheng, H., 2015. Niclosamide an anti-
helminthic molecule, downregulates the retroviral oncoprotein Tax and pro-
survival Bcl-2 proteins in HTLV-1-transformed T lymphocytes. Biochem.
Biophys. Res. Commun. 464, 221–228.
Zhang, X., Jackson, J.K., Burt, H.M., 1996. Determination of surfactant critical micelle
concentration by a novel ﬂuorescence depolarization technique. J. Biochem.
Biophys. Methods 31, 145–150.
Zhang, W., Shi, Y., Chen, Y., Ye, J., Sha, X., Fang, X., 2011. Multifunctional Pluronic
P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of
multidrug resistant tumors. Biomaterials 32, 2894–2906.
Zhu, P., Zhao, N., Sheng, D., Hou, J., Hao, C., Yang, X., Zhu, B., Zhang, S., Han, Z., Wei, L.,
Zhang, L., 2016. Inhibition of growth and metastasis of colon cancer by
delivering 5-ﬂuorouracil-loaded pluronic P85 copolymer micelles. Sci. Rep. 6,
20896.
d’Angelo, I., Conte, C., Miro, A., Quaglia, F., Ungaro, F., 2014. Core-shell nanocarriers
for cancer therapy: part I: biologically oriented design rules. Expert Opin. Drug
Deliv. 11, 283–297.
d’Emmanuele, V.d., Mitidieri, E., Esposito, D., Donnarumma, E., Russo, A., Fusco, F.,
Ianaro, A., Mirone, V., Cirino, G., Russo, G., Sorrentino, R., 2015. Human
cystathionine-beta-synthase phosphorylation on serine227 modulates
hydrogen sulﬁde production in human urothelium. PLoS One 10, e0136859.
